-
Sector Analysis
Acute Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2029
Acute Lymphocytic Leukemia (ALL) is a rare blood malignancy that affects the bone marrow and peripheral blood and originates from either B- or T-cells. While high long term overall survival (OS) rates have been achieved with the use of chemotherapy in children, outcomes in adults are suboptimal and outcomes for patients with T-ALL specifically have always been dismal. Prior to 2015, the main treatment options comprised various chemotherapy regimens and tyrosine kinase inhibitors (TKIs) such as Novartis’ Gleevec/Glivec (imatinib) or...
-
Sector Analysis
Small Cell Lung Cancer – Opportunity Analysis and Forecasts to 2029
The small cell lung cancer (SCLC) market has experienced moderate growth since 2016, and is expected to increase further, from $698m in 2019 to $2.4bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate of 12.9%. Growth will be driven by the anticipated launch of 10 pipeline agents and greater market access across the 8MM for premium priced agents. This report notes that the main barriers for market growth include the absence of predictive biomarkers...
-
Sector Analysis
OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) – Global Drug Forecast and Market Analysis to 2024
Hodgkin's lymphoma (HL), or Hodgkin's disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good. However, treatment options for those patients who have failed first-line treatment are very few, and a significant unmet medical need remains in those patients. GlobalData estimated the HL market in the 7MM was valued at...
-
Sector Analysis
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) – Opportunity Analysis and Forecasts to 2024
Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades. For the purposes of this report,...
-
Sector Analysis
PharmaPoint: Melanoma – Global Drug Forecast and Market Analysis to 2026
Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared with other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviolet (UV) exposure. Since 2011, the FDA/EMA have approved four immunotherapies, starting with the CTLA-4 targeting mAb, Yervoy (ipilimumab, Bristol-Myers Squibb), followed by PD-1 targeting mAbs, Keytruda (pembrolizumab, Merck & Co) and Opdivo (nivolumab, Ono/Bristol-Myers Squibb) and finally, oncolytic viral therapy,...
-
Sector Analysis
PharmaPoint: Prostate Cancer – Global Drug Forecast and Market Analysis to 2026
The prostate cancer market is expected to experience a moderate growth between 2016 and 2026. The main drivers of growth will be the expected label expansion of second-generation hormonal agents into hormone-sensitive disease and non-metastatic castration resistant prostate cancer (nmCRPC), and the launch and uptake of nine new premium-priced therapies. Until now, the hormone sensitive setting has been dominated by the use of cheap first-generation hormonal agents, with the use of premium-priced second-generation hormonal agents (Xtandi and Zytiga) limited to...
-
Sector Analysis
PharmaPoint: Colorectal Cancer – Global Drug Forecast and Market Analysis to 2025
The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed CRC incidence, and the launch and uptake of premium-priced therapies. Traditionally, the CRC market has been dominated by two therapeutic classes: angiogenesis and EGFR inhibitors. However, the efficacy of these agents is limited by the insurgence of acquired resistance. Further, RAS...
-
Sector Analysis
Gastric and Gastroesophageal Junction Adenocarcinoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2019-2029
The Gastric and Gastroesophageal Junction Adenocarcinoma (G/GEJAC) market size across the 8MM was valued at $1.12 billion in 2019 and is forecast to grow at a CAGR of more than 15% during 2019-2029. Growth of the market will be driven by the recent expansions of Opdivo and Keytruda into the first-line metastatic setting, further expansions for multiple agents across the 8MM, and the launches of nine pipeline agents.
-
Sector Analysis
T-Cell Lymphomas Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030
The global T-Cell Lymphoma (TCL) market was valued at $956 million across the eight major pharmaceutical markets (8MM) in 2020. The market is projected to grow at a CAGR of more than 6% during the forecast period. The introduction of 14 new pipeline agents and label expansions for currently approved agents are key drivers of this market growth. TCL is a rare type of cancer that forms in T-cells and is either indolent (slow-growing) or aggressive. TCL either develops in...
-
Sector Analysis
Cervical Cancer Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2020-2030
The cervical cancer (CC) market was valued at $607 million in the 8 major markets (8MM) in 2020. The market is projected to grow at a CAGR of more than 22% during the forecast period. The cervical cancer market report provides an overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It includes a 10-year epidemiological forecast for diagnosed...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.